摘要
高剂量治疗(HDT)后自体干细胞移植(ASCT)仍然是年龄在65岁以下多发性骨髓瘤(MM)患者的护理标准。然而这种治疗方法在过去十年中已经取得了重大进展,主要是由于引入了新药,如沙利度胺,来那度胺和硼替佐米。这些不同组合的新药显示出在诱导治疗和ASCT后显著提高了应答率。此外,ASCT在巩固和维护策略中获得的积极成果强烈支持持续治疗的概念,其最终目标是对疾病的长期控制和治疗结果的改善。调查下一代蛋白酶体抑制剂(如卡菲霉素和ixazomib)的研究的初步数据在前期以及随后的治疗线路中使用,显示了在大多数患者中获得分子缓解的可能性。通过新的药物组合获得的更深层次的反应质疑了ASCT的作用,大量正在进行的第3阶段试验将揭示ASCT的作用和时机。
关键词: 干细胞移植,多发性骨髓瘤,ASCT,蛋白酶体抑制剂,carfilzomib,ixazomib
图形摘要
Current Cancer Drug Targets
Title:Stem Cell Transplantation in Multiple Myeloma
Volume: 17 Issue: 9
关键词: 干细胞移植,多发性骨髓瘤,ASCT,蛋白酶体抑制剂,carfilzomib,ixazomib
摘要: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains the standard of care for patients younger than 65 years of age with multiple myeloma (MM). However, this therapeutic approach has undergone substantial advances in this last decade, mainly due to the introduction of new drugs such as thalidomide, lenalidomide and bortezomib. These new drugs, in different combinations, have shown to significantly increase response rates after induction therapy and ASCT. Moreover, the positive results obtained with these agents in consolidation and maintenance strategies after ASCT strongly support the concept of continuous therapy, whose ultimate goal is the long-term control of the disease and the improvement of outcome. Preliminary data from studies investigating next generation proteasome inhibitors, such as carfilzomib and ixazomib, used upfront as well as at subsequent therapeutic lines, demonstrate the possibility of achieving molecular remission in most of the patients. The deeper responses obtained with new drugcombinations questioned the role of ASCT, and large, ongoing, phase 3 trials will shed light on the role and the timing of ASCT.
Export Options
About this article
Cite this article as:
Stem Cell Transplantation in Multiple Myeloma, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009616666160920090236
DOI https://dx.doi.org/10.2174/1568009616666160920090236 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Meeting Report: The Fourth Annual PepTalk Meeting: The Human Proteome
Current Proteomics Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design The Role of the O-GlcNAc Modification in Regulating Eukaryotic Gene Expression
Current Signal Transduction Therapy Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Effect of Lithium on Neurocognitive Functioning
Current Alzheimer Research Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry Biosynthesis of Anti-Proliferative Gold Nanoparticles Using Endophytic Fusarium oxysporum Strain Isolated from Neem (A. indica) Leaves
Current Topics in Medicinal Chemistry Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Discovery of Novel HDAC Inhibitors by Structure-based Optimization of Cinnamic Hydroxamic Scaffold
Letters in Drug Design & Discovery Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets Editorial [Hot topic: Developing New Anti-Cancer Drugs (Guest Editor: Ricardo De Souza Pereira)]
Recent Patents on Anti-Cancer Drug Discovery